

Company Overview

Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB) is a leader in precision medicine with immuno-targeted products designed to help identify the sites and pathways of undetected disease and enable better diagnostic accuracy, clinical decision-making, targeted treatment and, ultimately, patient care. Applying our Manocept™ technology, Navidea seeks to develop next-generation targeted diagnostics and therapies for cancer, autoimmune conditions, and other inflammatory diseases. The company, founded in 1983, maintains headquarters in Dublin, Ohio.

Navidea Biopharmaceuticals Announces First 110 Subjects Imaged in NAV3-35 Normative Database Phase 2b Study to Support Rheumatoid Arthritis Indications

Jul 19 2021, 7:30 AM EDT

Navidea Biopharmaceuticals Announces End-of-Phase 2 Type B Meeting Request Granted by the FDA to Discuss Ongoing Clinical Program in Rheumatoid Arthritis

Jul 15 2021, 7:30 AM EDT

Macrophage Therapeutics, Inc. Wins Delaware Case Against Michael Goldberg for Breach of Fiduciary Duty

Jun 24 2021, 7:00 AM EDT

Stock Overview

Symbol NAVB
Exchange NYSE American
Market Cap 48.76m
Last Price \$1.68
52-Week \$1.46 - \$5.02

07/30/2021 03:59 PM EDT

Investor Relations

Jed A. Latkin
Chief Executive Officer, Chief
Operating Officer and Chief
Financial Officer
T: 614-973-7490
jlatkin@navidea.com

Management Team

Jed A. Latkin

Chief Executive Officer, Chief Financial Officer and Chief Operating Officer

William Regan

Chief Compliance Officer

Michael Rosol, Ph.D.

Chief Medical Officer

Navidea Biopharmaceuticals, Inc.

4995 Bradenton Avenue
Suite 240
Dublin, OH 43017

Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.